NEWS

  • R&D
Updated References
  • R&D
KORTUC’s clinical research result of unresectable recurrent uterine cervical cancer will be presented at ABS Annual Conference in Denver
  • R&D
KORTUC’s therapy and its related basic research is to be presented by Dr. Navita Somaiah, Chief Principal Investigator of the ongoing pivotal KORTUC P2, at ARR 2022
  • R&D
Results showing high efficacy and tolerable safety of Kortuc in several radioresistant cancer types were published in Molecular and Clinical Oncology. This shows KORTUC has potential to treat various types of cancer that are radioresistant
  • R&D
KORTUC Inc. started research collaboration with Okayama University on the tumor immunity by a novel radiosensitizer
  • R&D
Results showing high efficacy of Kortuc in treating locally advanced or recurrent breast cancer were published in Molecular and Clinical Oncology. These predict a positive outcome of the current pivotal Phase 2 study
  • R&D
KORTUC’s basic research result of tumor reoxygenation was presented at ESTRO 2021
  • R&D
Rationale and outcome in various cancer types in clinical practices in Japan were presented at ENA
  • R&D
Outcomes of various cancer types used in clinical practices in Japan were presented at IAEA
  • R&D
KORTUC Pivotal Phase 2 study is commenced in the UK